Huiyu Pharmaceutical (688553.SH) subsidiary's clinical trial application for injection HY07121 (subcutaneous injection) has been accepted.
Huayu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary, Sichuan Huayu Haiyue Medical Technology Co., Ltd., recently received the "Acceptance Notice" issued by the National Medical Products Administration for the clinical trial application of injection HY07121 (subcutaneous injection) (project research and development code "HY0007") for the treatment of advanced solid tumors. The drug was approved for intravenous administration in September 2024 and is currently in phase I clinical trials.
Huoyu Pharmaceuticals (688553.SH) announced recently that its wholly-owned subsidiary, Sichuan Huoyu Haiyue Medical Technology Co., Ltd., received an "Acceptance Notification" from the National Medical Products Administration for the clinical trial application of injection HY07121 (subcutaneous injection) for the treatment of advanced solid tumors (project research and development code "HY0007"). The drug was approved for intravenous administration in September 2024 and is currently in Phase I clinical trials.
Related Articles
ZIJING INTL FIN(08340): Executive Director Ma Jian appointed as Chairman of the Board.
On June 15th, Blue Moon Group (06993) spent HK$11.1499 million to repurchase 3.646 million shares.
WuXi AppTec (02359) spent 102 million Hong Kong dollars on repurchasing 818,000 shares on June 15th.
ZIJING INTL FIN(08340): Executive Director Ma Jian appointed as Chairman of the Board.
On June 15th, Blue Moon Group (06993) spent HK$11.1499 million to repurchase 3.646 million shares.
WuXi AppTec (02359) spent 102 million Hong Kong dollars on repurchasing 818,000 shares on June 15th.
RECOMMEND
